bluebird bio (BLUE) reports revenue at $18.6 million, provides guidance

bluebird bio (NASDAQ: BLUE) reported revenue for the quarter came in at $18.6 million versus the consensus estimate of $19.54 million.

2024 GUIDANCE

The Company anticipates 85 to 105 patient starts (cell collections) combined across all three of its FDA approved therapies (LYFGENIA, ZYNTEGLO, SKYSONA) in 2024. Consistent with previous quarters, bluebird plans to provide quarterly updates on patient starts for each of its therapies.
Gross-to-net discounts across all three products are expected to be in the range of 20% to 25% of gross revenue in 2024 and will fluctuate based on product and payer mix, as well as utilization of outcomes-based agreements for LYFGENIA and ZYNTEGLO.
Based on projected timelines from cell collection to infusion, the Company anticipates recognizing revenue from its first infusion of LYFGENIA in the third quarter of 2024.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• Investing.com’s stocks of the week